Search Results
Your search for Staff,Staff matches 6923 pages
Showing 1 - 50Firefighters May Face Higher Risk of Gliomas Associated With Gene Mutations Caused by Haloalkanes
Among patients with gliomas, gene mutations related to exposure to certain chemical compounds may be more common in firefighters than in those with other occupations, according to a recent study published by Cannataro et al in Cancer. Background Certain chemical compounds have been known to cause...
Moderate-to-Vigorous Physical Activity May Lower Risk of Cardiovascular Disease–Related Mortality in Women With a Cancer History
Taking more daily steps and engaging in moderate-to-vigorous physical activity may both be associated with a reduced risk of cardiovascular disease–related mortality among postmenopausal women with a history of cancer, according to preliminary findings presented by Hyde et al at the American Heart...
Two Initiatives Could Help Increase Oncogene Testing in Primary Care Settings
Investigators may have identified new strategies for use in the primary care setting to improve the detection of cancer-susceptibility genes, according to a recent study published by Swisher et al in JAMA Network Open. Background Up to 10% of cancers—including breast cancer, ovarian cancer,...
Liquid Biopsies Could Help Guide Colorectal Cancer Treatment
The use of a circulating tumor DNA (ctDNA) liquid biopsy to guide colorectal cancer treatment in the adjuvant setting may not compromise outcomes despite allowing many patients to avoid chemotherapy, according to a recent study published by Tie et al in Nature Medicine. Background A liquid biopsy...
Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma
The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...
Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer
Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma, according to a recent study published by Rosenberg et al in...
ACS Awards Dr. W. Kimryn Rathmell the 2025 Medal of Honor
In recognition of her commitment to tackling the complexities and challenges of cancer, the American Cancer Society (ACS) awarded the 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, MMHC. The Medal of Honor is the American Cancer Society’s most prestigious award given to distinguished...
Greater Plant-Based Oil, Lower Butter Intake Could Improve Risk of Cancer-Related Mortality
Investigators have found that the consumption of plant-based oils instead of butter may provide beneficial health effects and potentially reduce the risk of premature mortality, according to recent findings presented at the American Heart Association Epidemiology, Prevention, Lifestyle &...
Breast Cancer Mortality Rates May Have Stopped Declining
Breast cancer mortality rates may have stopped declining in women older than 74 years and younger than 40 years, according to a recent study published by Monticciolo and Hendrick in the Journal of Breast Imaging. Background Breast cancer is the second leading cause of cancer-related mortality among ...
Partial-Gland Removal May Be an Option for Many Men With Prostate Cancer
A 5-year study on men that had primary partial-gland cryoablation shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function. Led by researchers at New York University Grossman School of Medicine, the study tracked the patient outcomes after...
SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer
A common type of diabetes drug known as sodium-glucose cotransporter-2 (SGLT2) inhibitors could help patients with cancer achieve greater long-term recovery, according to a novel study published by Bhalraam et al in the European Journal of Preventive Cardiology. Background Many patients with cancer ...
Genetic Factors Could Illuminate Which Patients With Prostate Cancer Could Benefit From Combination of Ipatasertib Abiraterone
Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology. Background Prostate cancer...
Novel Biomarkers May Improve Diagnosis of Gallbladder Cancer
Plasma proteins may be capable of distinguishing gallbladder cancer from cholecystitis, which could reduce unnecessary procedures and improve treatment options in patients with suspected gallbladder cancer, according to a recent study published by Nouairia et al in JHEP Reports. Gallbladder cancer...
Consumer Survey Reveals Common Misconceptions About HPV and HPV-Related Cancer
A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
MSTFCRC Updates Recommendations for Colonoscopy Preparation
Updated consensus recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer (MSTFCRC) address optimizing the quality of bowel preparation for colonoscopy. The document, published today by Jacobson et al, presents clinical strategies to improve bowel preparation as they apply...
Postradiotherapy Survival in Patients With Glioblastoma Multiforme and Low-Grade Gliomas
Investigators may have uncovered how radiotherapy affects survival in patients with glioblastoma multiforme and low-grade glioma, according to a recent study published by Veviorskiy et al in Aging. The findings highlighted key biological differences between these cancer types. Background...
Is There a Link Between Tattoos and Increased Cancer Risk?
Skin cancers and lymphoma may be more prevalent among individuals with tattoos compared with those without tattoos, according to a recent study published by Clemmensen et al in BMC Public Health. Prior research has shown that tattoo ink does not just remain at the site of injection—instead, when...
Francis S. Collins, MD, PhD, Retires From the National Institutes of Health
Francis S. Collins, MD, PhD, announced in a statement his retirement as Director of the National Institutes of Health (NIH), effective February 28, 2025. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years—Barack...
Novel Prediction Score May Estimate Risk of Early-Onset Colorectal Cancer, Precancerous Polyps
Researchers have developed and validated a novel prediction model that may be capable of estimating the risk of colorectal cancer and advanced precancerous polyps in patients younger than 45 years, according to a recent study published by Wehbe et al in Digestive Diseases and Sciences. Background...
Chemotherapy, Endocrine Therapy May Have Different Long-Term Physical Health Effects in Breast Cancer Survivors
The receipt of chemotherapy or endocrine therapy without chemotherapy could be associated with different long-lasting physical health declines among breast cancer survivors compared with those without breast cancer, according to a recent study published in JAMA Network Open. Background Physical...
Combination of MCL-1 and SRC Inhibitors May Increase Cell Death in AML
An innovative combination of treatment strategies involving myeloid cell leukemia (MCL)-1 inhibitors and a kinase inhibitor targeting the SRC oncogene could be effective at triggering cell death in acute myeloid leukemia (AML) cells, according to a recent study published by Hu et al in Signal...
Decoding Varying Risk of Colorectal Cancer Among Different Steatotic Liver Disease Subgroups
Investigators have found that the risk of colorectal cancer may vary among steatotic liver disease subgroups and could be higher in patients with alcoholic liver disease, according to a recent study published by Kimura et al in Clinical Gastroenterology and Hepatology. Background Lifestyle-related...
Breast-Conserving Surgery Linked to Improved Sexual Well-Being Compared With Postmastectomy Breast Reconstruction
Breast-conserving therapy may be associated with improved sexual well-being compared with mastectomy followed by breast reconstruction in patients with breast cancer, according to a recent study published by Stern et al in Plastic and Reconstructive Surgery. Background Many patients with breast...
Bacterial Leakage Across Gastric Lining Could Signify Cancer Risk
Researchers may have uncovered insights into the role of bacteria in the development of gastric cancer, according to a novel study published by Giddings et al in Helicobacter. The findings could pave the way for a more effective precancer treatment option. Background Gastric cancer is the fourth...
ASTRO Issues Clinical Guideline on Radiation Therapy for Anal Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin. The guideline, ASTRO’s first for anal cancer, is published in...
Participation in Early Trials May Provide Some Patients With Access to Cancer Drugs Later FDA Approved
Nearly 20% of patients participating in middle-stage cancer drug trials may receive treatments that eventually receive U.S. Food and Drug Administration (FDA) approval, according to a recent study published by Ouimet et al in the Journal of the National Cancer Institute. The findings may have...
BRCA1 Gene Mutations May Not Be Key to Prostate Cancer
Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...
Novel Antibody-Toxin Conjugate Evaluated in Early Study
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published in Nature Cancer, the new approach combined the benefits of antibody-drug...
New Study Uncovers Low Uptake of Supportive Care at End of Life in Patients With Advanced Cancer
Investigators have found that nearly 50% of patients with advanced cancer may receive potentially aggressive treatment at the expense of supportive care, despite considerable efforts to improve the quality of end-of-life care in the United States, according to a recent study published by Kwon et al ...
Physical Activity May Help Colorectal Cancer Survivors Live as Long as Those in General Population
Physical activity may help colorectal cancer survivors achieve long-term survival rates comparable to those of individuals in the general population, according to a recent study published by Brown et al in Cancer. Background Patients with colorectal cancer often face higher rates of premature...
Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC
Michael Schweizer, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses findings from a randomized dose-expansion study of the investigational EZH2 inhibitor mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer...
Masumi Ueda Oshima, MD, on, a Posttransplant GVHD Prophylaxis Strategy
Masumi Ueda Oshima, MD, of Fred Hutchinson Cancer Center, discusses findings from a phase II trial exploring the use of cyclosporine and sirolimus combined with mycophenolate mofetil or posttransplant cyclophosphamide as graft-vs-host disease (GVHD) prophylaxis.
John Magenau, MD, on Alpha-1-Antitrypsin for High-Risk Acute GVHD
John Magenau, MD, of the University of Michigan, presents results from the phase III BMT CTN 1705 trial, which explored the efficacy of alpha-1-antitrypsin (AAT) plus corticosteroids vs corticosteroids alone for the treatment of high-risk acute graft-vs-host disease (GVHD) following allogeneic...
Cancer Mortality Rates Among Black Patients vs Other Racial, Ethnic Groups
Although the cancer mortality rate among Black patients in the United States has dropped over the past 30 years, this patient population may continue to experience a disproportionately elevated cancer burden compared with other patient populations, according to a recent study published by Saka et...
Text Message Platform May to Help Address ‘Time Toxicity’ in Patients With Cancer
Digital technology may help to safely reduce the amount of time some patients with cancer spend receiving care—also referred to as “time toxicity”—according to a recent study published by Bange et al in NEJM Catalyst. Background Patients with cancer often spend a large amount of time on activities...
Kristina Maas-Bauer, MD, on ROCK1/2 Inhibition and GVHD
Kristina Maas-Bauer, MD, of the University of Freiburg, discusses preclinical research on the role of ROCK1/2 in graft-vs-host disease (GVHD), which found an effect on myeloid cells, both in phenotype profile and migration capabilities. Additionally, she discusses the potential of combining ROCK1/2 ...
Neeraj Agarwal, MD, FASCO, on mCRPC: Talazoparib Plus Enzalutamide as First-Line Treatment
Neeraj Agarwal, MD, FASCO, of Huntsman Cancer Institute, presents data from cohort 1 of the phase III TALAPRO-2 trial—final overall survival data, an update on radiographic progression–free survival, and safety follow-up—which included patients with metastatic castration-resistant prostate cancer...
Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2
Karim Fizazi, MD, PhD, of Institut Gustave Roussy, University of Paris-Saclay, reviews final overall survival results from cohort 2 of the phase III TALAPRO-2 trial, which investigated the combination of talazoparib and enzalutamide in patients with homologous recombination repair (HRR)-deficient...
Betty Hamilton, MD: Research Highlights in GVHD
Betty Hamilton, MD, of Cleveland Clinic, outlines key data from a clinical session she co-chaired on graft-vs-host disease (GVHD), including the role of JAK inhibitors in the prevention of the condition and novel therapies for the management of acute GVHD.
William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer
William Aronson, MD, of the VA Greater Los Angeles Healthcare System, discusses findings from the CAPFISH-3 trial, which investigated whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules decreased Ki-67 levels in men with prostate cancer on active surveillance (Abstract 312).
Genetic Testing May Identify High-Risk Cytogenetic Abnormalities in Patients With Multiple Myeloma
Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....
Adding Tumor Deposit Status to Cancer Staging May Improve Prognostication in Colorectal Cancer
Investigators assessed whether adding tumor deposit status to colorectal cancer staging may enhance prognostication, according to a recent study published by Sassun et al in JAMA Surgery. Background In patients undergoing surgical treatment of colorectal cancer, tumor deposits are defined as...
Masood Moghul, PhD, on a Mobile Prostate Cancer Clinical Unit: Findings From the Man Van
Masood Moghul, PhD, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, describes the impact of a nurse-led mobile clinical unit on targeted screening invitations to men at high risk for prostate cancer in disadvantaged communities in London (Abstract 317).
Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs
Omid Yazdanpanah, MD, of the University of California, Irvine, presents findings from a secondary analysis of the VISION trial, which compared the efficacy and safety of LuPSMA in patients treated with vs without concomitant androgen receptor pathway inhibitors (ARPIs) (Abstract 121).
Racial, Ethnic Disparities in Diagnostic Procedures Following Abnormal Mammograms
Investigators may have uncovered racial and ethnic disparities in the receipt of same-day diagnostic services and biopsies following abnormal mammogram findings in spite of the similar availability of diagnostic technologies, according to a recent study published by Lawson et al in Radiology....
Safety of Ceasing Combination Therapy After 2 Years in Patients With Renal Cell Carcinoma
Ceasing or pausing a combination of the immune checkpoint inhibitor nivolumab and the oral tyrosine kinase inhibitor (TKI) axitinib after 2 years may be safe among patients with metastatic renal cell carcinoma who achieved a positive response to this treatment, according to updated analysis of a...
Cancer, Aging, and Meaning: Navigating Psychosocial Challenges
I’ve learned a lot about medicine over the years, but one thing I wasn’t taught was how to guide someone through the existential weight of dying. My education centered on diagnosing, curing, or at least managing disease—not on the delicate art of helping people and their loved ones cope with what...
Vimseltinib Approved by the FDA for Symptomatic TGCT
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. MOTION Trial Efficacy was...
Comprehensive CT Scans May Help to Identify Atherosclerosis Among Patients With Lung Cancer
Several cardiovascular risk factors such as advanced age and smoking history may be prevalent among patients with lung cancer at the time of diagnosis and may increase their risk of future cardiovascular disease, according to findings presented by Malozzi et al at the American College of...
Are Immune Checkpoint Inhibitors Effective in Hospitalized Patients With Cancer?
Immune checkpoint inhibitors may be ineffective among patients hospitalized with cancer, according to a recent study published by Riaz et al in JCO Oncology Practice. Background Immune checkpoint inhibitors have transformed treatment for many cancer types but are often restricted for inpatient use...
